Silence Therapeutics agrees to Merck KGaA takeover at 130% premium
FROM THE WIRE · GURUFOCUS.COM
The U.S.-listed biotechnology company Silence Therapeutics (SLN, Financials) consented to Merck KGaA's purchase in an all-cash transaction worth roughly $1.3 bi
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA cash offer at a high premium for a U.S.-listed biotech anchors the share price.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Silence Therapeutics consented to Merck KGaA's purchase.
- 02The all-cash transaction is worth roughly $1.3 billion.
- 03The takeover premium is 130%.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets